The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long qt syndrome type 3 patients

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Fatima, Azra ^a   Kaifeng, Shao ^a   Dittmann, Sven ^b,c   Xu, Guoxing ^a   Gupta, Manoj K ^a   Linke, Matthias ^d   Zechner, Ulrich ^d   Nguemo, Filomain ^a   Milting, Hendrik ^b,c   Farr, Martin ^b,c   Hescheler, Jürgen ^a   Šarić, Tomo ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Erich and Hanna Klessmann Institute for Cardiovascular Research and Development   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHANNEL; SODIUM CHANNEL NAV1.5; SCN5A PROTEIN, HUMAN;

ADULT; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; FAINTNESS; FEMALE; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; LONG QT SYNDROME 3; MALE; MEMBRANE POTENTIAL; PLURIPOTENT STEM CELL; POINT MUTATION; SODIUM CURRENT; TACHYCARDIA; TORSADE DES POINTES; ACTION POTENTIAL; CELL CULTURE; CLINICAL TRIAL; GENETICS; LONG QT SYNDROME; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ACTION POTENTIALS; ADULT; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MEMBRANE POTENTIALS; MYOCYTES, CARDIAC; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PLURIPOTENT STEM CELLS; POINT MUTATION;

EID: 84892429611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083005     Document Type: Article

References (37)

1. Napolitano C, Priori SG, Schwartz PJ (1994) Torsade de pointes. Mechanisms and management. Drugs 47: 51-65. doi: 10.2165/00003495-199447010- 00004. PubMed: 7510621.
2. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E et al. (2003) Risk stratification in the long-QT syndrome. N Engl J Med 348: 1866-1874. doi:10.1056/NEJMoa022147. PubMed: 12736279.
3. Refsgaard L, Holst AG, Sadjadieh G, Haunsø S, Nielsen JB et al. (2012) High prevalence of genetic variants previously associated with LQT syndrome in new exome data. Eur J Hum Genet 20: 905-908. doi: 10.1038/ejhg.2012.23. PubMed: 22378279.
4. Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E (1985) The long QT syndrome: a prospective international study. Circulation 71: 17-21. doi:10.1161/01.CIR.71.1.17. PubMed: 2856865.
5. Bennett PB, Yazawa K, Makita N, George AL Jr. (1995) Molecular mechanism for an inherited cardiac arrhythmia. Nature 376: 683-685. doi:10.1038/376683a0. PubMed: 7651517.
6. Napolitano C, Rivolta I, Priori SG (2003) Cardiac sodium channel diseases. Clin Chem Lab Med 41: 439-444. PubMed: 12747584.
7. Remme CA, Wilde AAM, Bezzina CR (2008) Cardiac Sodium Channel Overlap Syndromes: Different Faces of SCN5A Mutations. Trends Cardiovasc Med 18: 78-87. doi:10.1016/j.tcm.2008.01.002. PubMed: 18436145.
8. Baroudi G, Chahine M (2000) Biophysical phenotypes of SCN5A mutations causing long QT and Brugada syndromes. FEBS Lett 487: 224-228. doi:10.1016/S0014-5793(00)02360-7. PubMed: 11150514.
9. Hedley PL, Jørgensen P, Schlamowitz S, Moolman-Smook J, Kanters JK et al. (2009) The genetic basis of Brugada syndrome: a mutation update. Hum Mutat 30: 1256-1266. doi:10.1002/humu.21066. PubMed: 19606473.
10. Nuyens D, Stengl M, Dugarmaa S, Rossenbacker T, Compernolle V et al. (2001) Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med 7: 1021-1027. doi:10.1038/nm0901-1021. PubMed: 11533705.
11. Papadatos GA, Wallerstein PM, Head CE, Ratcliff R, Brady PA et al. (2002) Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci U S A 99: 6210-6215. doi:10.1073/pnas.082121299. PubMed: 11972032.
12. Davis RP, Casini S, van den Berg CW, Hoekstra M, Remme CA et al. (2012) Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125: 3079-3091. doi:10.1161/CIRCULATIONAHA.111. 066092. PubMed: 22647976.
13. Malan D, Friedrichs S, Fleischmann BK, Sasse P (2011) Cardiomyocytes Obtained From Induced Pluripotent Stem Cells With Long-QT Syndrome 3 Recapitulate Typical Disease-Specific Features In Vitro / Novelty and Significance. Circ Res 109: 841-847. doi:10.1161/CIRCRESAHA.111.243139. PubMed: 21799153.
14. Moretti A, Bellin M, Welling A, Jung CB, Lam JT et al. (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363: 1397-1409. doi:10.1056/NEJMoa0908679. PubMed: 20660394.
15. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O et al. (2011) Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471: 225-229. doi:10.1038/nature09747. PubMed: 21240260.
16. Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M et al. (2012) Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model. Journal of Mech 5: 220-230.
17. Matsa E, Rajamohan D, Dick E, Young L, Mellor I et al. (2011) Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 32: 952-962. doi:10.1093/eurheartj/ehr073. PubMed: 21367833.
18. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872. doi:10.1016/j.cell.2007.11.019. PubMed: 18035408.
19. Fatima A, Xu G, Shao K, Papadopoulos S, Lehmann M et al. (2011) In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem 28: 579-592. doi: 10.1159/000335753. PubMed: 22178870.
20. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S et al. (2003) Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 107: 2733-2740. doi:10.1161/01.CIR. 0000068356.38592.68. PubMed: 12742992.
21. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S et al. (2003) Differentiation of Human Embryonic Stem Cells to Cardiomyocytes. Circulation 107: 2733-2740. doi: 10.1161/01.CIR.0000068356.38592.68. PubMed: 12742992.
22. Tost J, Dunker J, Gut IG (2003) Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. BioTechniques 35: 152-156. PubMed: 12866415.
23. Makielski JC, Ye B, Valdivia CR, Pagel MD, Pu J et al. (2003) A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ Res 93: 821-828. doi:10.1161/01.RES. 0000096652.14509.96. PubMed: 14500339.
24. Viswanathan PC, Benson DW, Balser JR (2003) A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. J Clin Invest 111: 341-346. doi:10.1172/JCI200316879. PubMed: 12569159.
25. Cheng J, Morales A, Siegfried JD, Li D, Norton N et al. (2010) SCN5A rare variants in familial dilated cardiomyopathy decrease peak sodium current depending on the common polymorphism H558R and common splice variant Q1077del. Clin. Transl Sci 3: 287-294.
26. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C et al. (2009) Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 6: 1297-1303. doi:10.1016/j.hrthm.2009.05.021. PubMed: 19716085.
27. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M et al. (2010) An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 7: 33-46. doi:10.1016/j.hrthm.2009.09.069. PubMed: 20129283.
28. Amin AS, Boink GJ, Atrafi F, Spanjaart AM, Asghari-Roodsari A et al. (2011) Facilitatory and inhibitory effects of SCN5A mutations on atrial fibrillation in Brugada syndrome. Europace 13: 968-975. doi:10.1093/europace/ eur011. PubMed: 21273195.
29. Crotti L, Marcou CA, Tester DJ, Castelletti S, Giudicessi JR et al. (2012) Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol 60: 1410-1418. doi:10.1016/j.jacc.2012.04.037. PubMed: 22840528.
30. Keller DI, Rougier JS, Kucera JP, Benammar N, Fressart V et al. (2005) Brugada syndrome and fever: genetic and molecular characterization of patients carrying SCN5A mutations. Cardiovasc Res 67: 510-519. doi:10.1016/j.cardiores. 2005.03.024. PubMed: 15890323.
31. Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ et al. (2002) Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 40: 350-356. doi: 10.1016/S0735-1097(02)01962-9. PubMed: 12106943.
32. Wehrens XH, Rossenbacker T, Jongbloed RJ, Gewillig M, Heidbüchel H et al. (2003) A novel mutation L619F in the cardiac Na+ channel SCN5A associated with long-QT syndrome (LQT3): a role for the I-II linker in inactivation gating. Hum Mutat 21: 552. doi:10.1002/humu.9137. PubMed: 12673799.
33. Zimmer T, Surber R (2008) SCN5A channelopathies-an update on mutations and mechanisms. Prog Biophys Mol Biol 98: 120-136. doi: 10.1016/j.pbiomolbio. 2008.10.005. PubMed: 19027780.
34. Terrenoire C, Wang K, Tung KW, Chung WK, Pass RH et al. (2013) Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol 141: 61-72. PubMed: 23277474.
35. Knollmann BC (2013) Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model? Circ Res 112: 969-976. doi:10.1161/CIRCRESAHA.112.300567. PubMed: 23569106.
36. Zhang XH, Haviland S, Wei H, Sarić T, Fatima A et al. (2013) Ca(2+) signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Cell Calcium 54: 57-70. doi:10.1016/j.ceca.2013.04. 004. PubMed: 23684427.
37. Ye B, Valdivia CR, Ackerman MJ, Makielski JC (2003) A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation. Physiol Genomics 12: 187-193. PubMed: 12454206.